Share
Fitbit has tapped alternative medicine advocate Dr. Deepak Chopra to headline a collection of wellness content for Fitbit Premium members.
Called Deepak Chopra s Mindful Method for Fitbit, the offering launches with 10 sessions focused on topics such as mindfulness, breathing, stress management and sleep, with additional sessions coming every couple of weeks up to the beginning of June, Fitbit said. The audio and video sessions run no longer than 20 minutes each. My Premium content will offer guided meditation and techniques that focus on the four pillars of wellbeing: mind, body, emotions, and spirit,” Chopra said in a statement. “My content draws inspiration from my own mindfulness techniques, which will help encourage you to evaluate and analyze your own state by answering the same questions and following the same thought process that I ask myself daily: Who am I? What do I want? What’s my purpose? What am I grateful for?”
Share this article
Share this article
FRANKLIN LAKES, N.J., Feb. 22, 2021 /PRNewswire/ BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Scanwell Health, a leader in smartphone-enabled at-home medical tests, today announced a collaboration to create an at-home rapid test for SARS-CoV-2 using a BD antigen test and the Scanwell Health mobile app.
As part of the collaboration, BD plans to produce a lateral flow antigen test and pair it with the Scanwell Health mobile app. The app is expected to provide step-by-step instructions on how to collect and transfer a nasal swab sample and use the mobile device s camera to analyze and interpret results. The test result will be displayed onscreen, and the companies are also planning to develop functionality to assist in automated reporting to public health agencies. This approach is intended to provide an efficient and scalable rapid antigen home testing solution.
Becton Dickinson is developing rapid COVID test for use at home bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.
FDA grants EUA to BD s SARS-CoV-2/Flu assay
FDA grants EUA to BD s SARS-CoV-2/Flu assay
15 February 2021 | News The BD® SARS-CoV-2/Flu assay is run on the BD MAX™ System and distinguishes between SARS-CoV-2 and Influenza A+B, providing a positive or negative result for each virus using a single specimen
Source: PR Newswire
BD (Becton, Dickinson and Company), a leading global medical technology company, has announced that the US Food and Drug Administration (FDA) has granted Emergency Use Authorisation (EUA) for a new molecular diagnostic test for both SARS-CoV-2 and Influenza A+B that can return results in two to three hours. The new test also has been CE marked to the IVD Directive (98/79/EC).